Rheumatic immune-related adverse events of checkpoint therapy for cancer: Case series of a new nosological entity

RMD Open

Volumn 3, Issue 1, 2017, Pages

  Calabrese, C ^a   Kirchner, E ^a   Kontzias, K ^a   Velcheti, V ^a   Calabrese, L H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmune Diseases; Inflammation; Multidisciplinary team care

Indexed keywords

ADALIMUMAB; ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; CHECKPOINT INHIBITOR; DURVALUMAB; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; IPILIMUMAB; METHOTREXATE; METHYLPREDNISOLONE; NIVOLUMAB; PEMBROLIZUMAB; PREDNISONE; TICILIMUMAB; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; AUTOIMMUNE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE STUDY; CLINICAL ARTICLE; COLITIS; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; MALE; MELANOMA; MIDDLE AGED; MONOTHERAPY; MYOSITIS; NEUROPATHY; NON SMALL CELL LUNG CANCER; PATIENT CARE; PNEUMONIA; RASH; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; THYROIDITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY;

EID: 85015958229     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2016-000412     Document Type: Article

References (11)

1. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450-61.
2. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76:43-50.
3. Donia M, Pedersen M, Svane IM. Cancer immunotherapy in patients with preexisting autoimmune disorders. Semin Immunopathol 2016. Published Online First 11 October 2016. .
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
5. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
6. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
7. Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016;13:473-86.
8. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse e vents with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54:139-48.
9. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, needs for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Onc 2015;33:3193-8.
10. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749-55.
11. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016;2:234-40.